KIN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KIN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Kindred Biosciences's total current assets for the quarter that ended in Jun. 2021 was $79.08 Mil.
The historical data trend for Kindred Biosciences's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindred Biosciences Annual Data | |||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||||||
Total Current Assets | Get a 7-Day Free Trial | 58.04 | 81.82 | 80.07 | 79.35 | 62.62 |
Kindred Biosciences Quarterly Data | ||||||||||||||||||||
Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | |
Total Current Assets | Get a 7-Day Free Trial | 72.77 | 67.76 | 62.62 | 79.09 | 79.08 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Kindred Biosciences's Total Current Assets for the fiscal year that ended in Dec. 2020 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 58.378 | + | 0.624 | + | 0.207 | + | 3.415 | |
= | 62.62 |
Kindred Biosciences's Total Current Assets for the quarter that ended in Jun. 2021 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 74.199 | + | 1.555 | + | 0 | + | 3.329 | |
= | 79.08 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Kindred Biosciences (NAS:KIN) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Kindred Biosciences's Liquidation Value for the quarter that ended in Jun. 2021 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 74.199 | - | 29.103 | + | 0.75 * 1.212 | + | 0.5 * 0 |
= | 46.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Kindred Biosciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Chin | director, officer: Chief Executive Officer | C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451 |
Park West Asset Management Llc | 10 percent owner | 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129 |
Denise Bevers | director | C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 |
Wendy Wee | officer: Chief Financial Officer | C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304 |
Hangjun Zhan | officer: Chief Scientific Officer | C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 |
Ernest Mario | director | 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928 |
Joseph S Mccracken | director | C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000 |
Herbert D Montgomery | director | C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066 |
Raymond Townsend | director | C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 |
Ervin Veszpremi | director | C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 |
Stephen Sundlof | officer: SVP of Regulatory Affairs | C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 |
Oleg Nodelman | director | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Selby Blake Hawley | officer: Chief Commercial Officer | C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010 |
Stephen S Galliker | officer: Chief Financial Officer | 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Kevin Schultz | officer: Chief Scientific Officer | C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010 |
From GuruFocus
By Marketwired Marketwired • 06-16-2021
By PRNewswire PRNewswire • 04-20-2021
By PRNewswire PRNewswire • 07-27-2021
By PRNewswire PRNewswire • 05-03-2021
By PRNewswire PRNewswire • 06-17-2021
By PRNewswire PRNewswire • 05-11-2021
By PRNewswire PRNewswire • 07-17-2021
By PRNewswire PRNewswire • 03-08-2021
By Marketwired Marketwired • 06-16-2021
By PRNewswire PRNewswire • 06-16-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.